Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Biogen (BIIB +0.4%) is upgraded to Buy from Neutral by Goldman Sachs, which says the risk/reward...

  • Wednesday, April 4, 2012, 9:32 AM ET
    Biogen (BIIB +0.4%) is upgraded to Buy from Neutral by Goldman Sachs, which says the risk/reward ratio is still attractive despite the stock's recent outperformance. The firm sees success of its BG-12 multiple sclerosis treatment supporting the current valuation, with "multiple optionalities for upside that are underestimated in Street estimates."
Track new comments on this story

This news story has 1 comment:

  •  
    I'm trying to understand why anyone in their right mind would pay attention to what Goldman Sachs has to say.
    4 Apr 2012, 11:54 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »